Health Care [ 9/12 ] | Biotechnology [ 65/74 ]
NASDAQ | Common Stock
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Feb 11, 25 | -0.33 Increased by +87.38% | -0.78 Increased by +57.03% |
Nov 11, 24 | -0.48 Increased by +82.78% | -0.55 Increased by +13.58% |
Sep 19, 24 | -1.32 Increased by +53.36% | -0.49 Decreased by -169.39% |
May 13, 24 | -1.64 Decreased by -925.00% | -0.78 Decreased by -110.26% |
Feb 13, 24 | -2.64 Decreased by -1.22 K% | -0.39 Decreased by -576.92% |
Nov 13, 23 | -2.76 Decreased by -487.23% | -0.51 Decreased by -441.18% |
Sep 21, 23 | -2.83 Decreased by -356.45% | -3.23 Increased by +12.38% |
May 15, 23 | -0.16 Increased by +60.00% | -0.20 Increased by +20.00% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 24 | 0.00 Decreased by N/A% | -7.36 M Decreased by -8.22% | Decreased by N/A% Decreased by N/A% |
Sep 30, 24 | 0.00 Decreased by N/A% | -5.06 M Increased by +15.03% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by -100.00% | -4.72 M Decreased by -1.27% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 6.00 K Decreased by -88.89% | -4.28 M Increased by +2.68% | Decreased by -71.32 K% Decreased by -775.85% |
Dec 31, 23 | 0.00 Decreased by -100.00% | -6.80 M Decreased by -30.43% | Decreased by N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by -100.00% | -5.95 M Decreased by -6.21% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 7.00 K Decreased by -72.00% | -4.66 M Increased by +8.01% | Decreased by -66.59 K% Decreased by -228.53% |
Mar 31, 23 | 54.00 K Increased by +12.50% | -4.40 M Decreased by -42.30% | Decreased by -8.14 K% Decreased by -26.49% |